Bong Y Koh
CIK 1615979 · last filed 2025-04-11
Bong Y Koh is a corporate insider who has filed 13 SEC Form 4 insider transactions across 5 companies since 2016. The most recent filing shows the insider bought $1.6M of KALV on Apr 11, 2025. Across all open-market trades the lifetime net is +$38.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $7.6M across reported positions. 55 SEC filings were submitted jointly with Nimish P Shah.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KALV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
23RD FLOOR
NEW YORK, NY 10018
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | 10%+ Owner | 5,303,985 | $27.00 | $143.21M | $19.15M | 4 | 2025-04-11 |
| Tricida, Inc. (TCDA) Delisted | 10%+ Owner | 7,607,951 | $0.11 | $821.7K | $14.57M | 2 | 2022-09-01 |
| ALT | 10%+ Owner | 3,500,000 | $2.17 | $7.59M | $0 | 1 | 2021-03-01 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | 10%+ Owner | 483,411 | $0.01 | $5.8K | $2.52M | 1 | 2018-09-17 |
| AveXis, Inc. (AVXS) Delisted | Director | 0 | — | — | $2.00M | 5 | 2018-05-15 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-11 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +175,000 | $1.65M | EDGAR |
| 2024-02-22 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | — | $0 | EDGAR |
| 2024-02-08 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +602,336 | $8.80M | EDGAR |
| 2024-01-24 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +693,903 | $8.69M | EDGAR |
| 2022-09-01 | Tricida, Inc. (TCDA) Delisted | Buy (P) | +500,000 | $6.10M | EDGAR |
| 2022-07-06 | Tricida, Inc. (TCDA) Delisted | Buy (P) | +882,000 | $8.47M | EDGAR |
| 2021-03-01 | ALT | Other (J) | −8,000,000 | $0 | EDGAR |
| 2018-09-17 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Buy (P) | +2,100,000 | $2.52M | EDGAR |
| 2018-05-15 | AveXis, Inc. (AVXS) Delisted | Disp (D) | −1,036,763 | $0 | EDGAR |
| 2018-03-30 | AveXis, Inc. (AVXS) Delisted | Grant (A) | +1,106 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.